GlassScriptPhysician profile
Jayne M Donovan
NPI 1407172794
$198.72
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $23.33 · 2022: $20.08.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $56.75 | 2019 | |
| Abbott Laboratories | $20.36 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $20.08 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.14 | 2019 | |
| Tersera Therapeutics LLC | $14.04 | 2019 | |
| Pacira Therapeutics, INC. | $13.26 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.17 | 2019 | |
| Collegium Pharmaceutical, INC. | $12.36 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.93 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.40 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.23 | 2019 |
Research and ownership
$139.09 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayne Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.